Brandon Imber, MD, MA
Radiation Oncologist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Lymphomas
- Intensity Modulated Radiation Therapy (IMRT)
- Image-Guided Radiation Therapy (IGRT)
About Me
- Assistant Attending Radiation Oncologist
I am a radiation oncologist who cares for people with blood cancers and tumors affecting the brain and central nervous system.
I see patients in Manhattan and our Regional Care Network on Long Island. As a graduate of Commack High School, I feel fortunate to be able to offer compassionate, state-of-the-art care to the communities where I grew up.
Read more
I received my bachelor’s and master’s degrees in chemistry from Harvard University. I earned my medical degree at the University of California, San Francisco, dedicating an additional year to research focused on the aggressive brain cancer glioblastoma. My specialty training was at Memorial Sloan Kettering, where I also completed a clinical research fellowship in lymphoma radiation oncology. As a resident, I obtained specialized training in clinical research at the Harvard School of Public Health.
I was drawn to oncology, and radiation oncology specifically, because of the strong bonds formed between patient and physician. A cancer diagnosis and the prospect of radiation therapy can be intimidating, overwhelming, and frightening. I believe that critical first steps are to communicate clearly to ease fears, provide full explanations of options, and answer questions. My team and I strive to be our patients’ unwavering advocates and aim to offer strong emotional and physical support at every step of the process.
When treating blood cancers like lymphoma, multiple myeloma, and leukemia, as well as certain brain tumors, I implement advanced radiation techniques including intensity modulated radiation therapy and image-guided radiation therapy to safely and effectively treat these cancers. For brain metastases and benign tumors, I often rely on highly focal modalities like MSK Precise™ stereotactic radiosurgery.
I am a strong believer in a multidisciplinary approach to patient care and am a member of several clinical teams, including the Lymphoma Disease Management Team and MSK’s Brain Metastasis Center. I work collaboratively with my patients’ other providers, including medical oncologists, surgeons, radiologists, and pathologists to develop a highly personalized care plan guided by the latest clinical evidence. I feel very strongly that patients and their families should be participants in this process to tailor the treatment plan according to specific goals and concerns.
In addition to caring for patients, I participate in several research programs which fall under two broad themes: improvement of outcomes and reduction of side effects for blood and brain cancer treatments. I am particularly interested in designing clinical trials which combine radiotherapy with other novel cancer therapies. For example, I am currently studying potential ways to combine radiation with highly innovative CAR T cell therapies to enhance treatment responses in aggressive lymphomas like diffuse large B-cell lymphoma. To minimize side effects and increase patient convenience, I am studying how we can safely reduce the number of radiation treatments necessary for less-aggressive lymphomas like cutaneous T-cell lymphomas. I am also working closely with colleagues in neurosurgery and neuro-oncology to evaluate new technologies for brain brachytherapy, a specialized way to deliver radiation in the operating room very focally to the edges of a surgical cavity while sparing much of the surrounding healthy brain tissue.
I feel privileged to practice at MSK given our ability to offer world-class treatment approaches including promising clinical trials which might not be available elsewhere. When I am not working, I enjoy spending time with my family, brewing craft coffee, running in Central Park, and hiking in upstate New York.
A radiation oncologist is a cancer doctor with special training in using radiation therapy (RT) to treat cancer with radiation.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Lymphomas
- Intensity Modulated Radiation Therapy (IMRT)
- Image-Guided Radiation Therapy (IGRT)
- Volumetric Arc Therapy (VMAT)
- Stereotactic Body Radiation Therapy (SBRT)
- Stereotactic Radiosurgery (SRS)
- MSK Precise for Brain Cancer
Education
- MA, Chemical Biology, Harvard University
- MD, University of California, San Francisco School of Medicine
- Certificate Program in Clinical Effectiveness, Harvard University T.H. Chan School of Public Health
Residencies
- Radiation Oncology - Memorial Sloan Kettering Cancer Center
Awards and Honors
- Chief Resident, Radiation Oncology, Memorial Sloan Kettering Cancer Center (2020)
- Abstract Award, American Society of Hematology (2019)
- Resident Research Grant, American College of Radiation Oncology (2018)
- Dr. Mortimer J. Lacher, MD Fellowship award in Lymphoma, Memorial Sloan Kettering Cancer Center (2018)
- Resident Essay Award, American College of Radiation Oncology (2017)
- Alpha Omega Alpha Medical Honor Society, UCSF (2014)
Fellowships
- Lymphoma Radiotherapy - Memorial Sloan Kettering Cancer Center
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Contact and Location
Dr. Imber sees patients at three locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
See all Early Drug Development Service doctors
See all External Beam Radiotherapy Service, Regional Care Network doctors
See all Radiation Oncology doctors
See all External Beam Radiotherapy Service, Manhattan doctors
Clinical Trials
- Clinical Trials Investigated by Dr. Imber
- A Phase I Study of AZD1390 plus Radiation Therapy in Patients with Glioblastoma Multiforme or Brain Metastases
- A Phase IB Study of Bexarotene Combined with Radiotherapy in People with Mycosis Fungoides
- A Phase III Study of Post-Surgical Stereotactic Radiotherapy versus Gamma Tiles to Treat Newly Diagnosed Brain Metastases
- Clinical Trials Co-Investigated by Dr. Imber
- A Phase I Study of Radiation Therapy Before CAR T Cell Therapy for People with B Cell Lymphoma
Read more
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Imber’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Brandon Imber discloses the following relationships and financial interests:
-
GT Medical Technologies, Inc.
Professional Services and Activities -
Ono Pharma
Professional Services and Activities
-
Telix Pharmaceuticals Limited
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].